GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maxygen, Inc. (FRA:MYN) » Definitions » Cash Receipts from Tax Refunds

Maxygen, (FRA:MYN) Cash Receipts from Tax Refunds


View and export this data going back to . Start your Free Trial

What is Maxygen, Cash Receipts from Tax Refunds?

Cash Receipts from Tax Refunds only applicable to companies reporting Cash Flow from Operations in direct method.

Maxygen, (FRA:MYN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maxygen, Inc. (FRA:MYN) » Definitions » Cash Receipts from Tax Refunds
Comparable Companies
CATB HKSE:08329 EQ TSE:4575 XMAD:BIO TSE:4583 XBRU:ASIT TSE:4570 LSE:OPTI ASX:OCC XPAR:OSE GNCA XPAR:ALQGC MRNS NLNK ASX:IMM OPNT TSE:7776 BKK:IP ASX:MDC
Traded in Other Exchanges
N/A
Address
Website
Maxygen, Inc., is incorporated in Delaware. It is a biotechnology company. It discovers and develops improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. The Company's MAXY-G34 product candidate has been designed to be an improved next-generation pegylated, G-CSF for the treatment of chemotherapy-induced neutropenia. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The Company completed a Phase IIa clinical trial for its MAXY-G34 product candidate for the treatment of chemotherapy-induced neutropenia in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia with no serious adverse events, drug-related grade 3 or 4 adverse events or immunogenicity reported in any patient receiving MAXY-G34. Adverse events were consistent with known side effects of G-CSF molecules. The Company is subject to regulation by the FDA and comparable regulatory agencies in foreign countries with respect to any development and commercialization of its MAXY-G34 product candidate or any other products it may acquire in the future.